Haleos Labs Limited has approved the reappointment of Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as independent directors for a second consecutive term of five years. The Board of Directors made the decision at its meeting held on August 5, 2026, based on the recommendation of the Nomination and Remuneration Committee. The new terms commence on November 13, 2026, subject to the approval of shareholders. This move ensures continuity in board oversight, with both directors bringing decades of specialized expertise in public administration and critical care medicine to the company’s governance structure.

The reappointment was disclosed to BSE Limited and National Stock Exchange of India Limited in compliance with Regulation 30 (6) read with sub-para 7 of para "A" of part "A" of Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The filing confirms that neither director is debarred from holding office by virtue of any SEBI order or other authorities, as per circulars NSE/CML/2018/02 and LIST/COMP/14/2018-19 dated June 20, 2018.

Director Profiles and Tenure

Both directors are completing their first tenure, which ends on November 12, 2026. Their reappointment marks the start of their maximum allowable second consecutive term under regulatory guidelines.

Dr. Mannam Malakondaiah, a distinguished 1985 Batch Indian Police Service officer, retired as Director General of Police, Andhra Pradesh, on June 30, 2018. He previously served as Vice-Chairman and Managing Director of APSRTC and has held senior roles in APTRANSCO and CISF. Currently an Honorary Advisor to Vignan University, he brings extensive experience in public administration and law enforcement to the board.

Dr. Srinivas Samavedam is a leading Critical Care Medicine specialist with over 26 years of experience. He serves as Consultant & Head – Critical Care at Sindhu Hospitals, Hyderabad, and is credited with introducing ECMO services in the city. His academic credentials include an MD and DNB in Internal Medicine, FNB in Critical Care Medicine, and a European Diploma in Intensive Care.

Committee Memberships

The filing details the committee compositions for both directors, highlighting their governance responsibilities within the company.

Dr. Mannam Malakondaiah:

• Audit Committee: Member
• Nomination and Remuneration Committee: Chairman
• Corporate Social Responsibility Committee: Member

Dr. Srinivas Samavedam:

• Nomination and Remuneration Committee: Member
• Corporate Social Responsibility Committee: Member

No relationship exists between the two directors, as confirmed in the disclosure. Detailed profiles are available on the company website.

Haleos Labs Limited reported a standalone net profit of ₹3.24 crore for the quarter ended June 30, 2026 (Q1FY27), marking a 45% increase from ₹2.23 crore in the preceding quarter. The improvement was primarily driven by a reduction in inventory costs, which contributed a negative expense of ₹7.83 crore, compared to ₹7.34 crore in March 2026. However, consolidated net profit attributable to equity holders declined 58% year-on-year to ₹2.65 crore from ₹4.16 crore in Q1FY26, reflecting higher material costs and lower operational revenue.

The Board of Directors held its 98th meeting on August 5, 2026, to approve the unaudited standalone and consolidated financial results as reviewed by the Audit Committee and statutory auditors Rambabu & Co. In compliance with Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company submitted these results to the BSE and NSE. The financial statements were prepared in accordance with Ind AS 34 and other generally accepted accounting principles in India.

Key Financial Metrics

Standalone revenue from operations rose 7% quarter-on-quarter to ₹67.83 crore but fell 14% year-on-year from ₹79.04 crore. Other income decreased significantly to ₹45.61 lakh from ₹100.94 lakh in the same period last year. On a consolidated basis, revenue from operations dropped 12% YoY to ₹72.94 crore. The subsidiary, Mahi Drugs Private Limited, reported a total revenue of ₹10.25 crore and a net loss after tax of ₹20.16 crore for the quarter, which management stated was not material to the Group.

Corporate Governance Actions

The Board approved several key governance matters subject to shareholder approval at the upcoming Annual General Meeting. These include the re-appointment of Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors for a second term of five years, effective November 13, 2026. Additionally, the Board sought approval for a revision in managerial remuneration for TVVSN Murthy, Managing Director.

The company scheduled its 20th Annual General Meeting for September 30, 2026, to be held via Video Conferencing or Other Audio Visual Means, in accordance with MCA General Circular No. 03/2025 and No. 09/2024. A detailed report pursuant to Schedule III of the SEBI LODR Regulations will be filed separately within the prescribed timeline.

What the Numbers Show

The divergence between standalone and consolidated performance highlights cost pressures in the supply chain. While standalone profitability improved due to inventory write-downs, consolidated margins faced headwinds from rising material costs, which increased to ₹40.14 crore from ₹27.73 crore year-on-year. This suggests that while Haleos Labs managed its own inventory efficiently, broader group-level input costs remain elevated, impacting overall bottom-line growth despite stable operational volumes.